William Blair Brokers Reduce Earnings Estimates for BMY

Bristol Myers Squibb Company (NYSE:BMY) – Equities researchers at William Blair dropped their Q2 2025 EPS estimates for Bristol Myers Squibb in a research note issued on Monday, July 14th. William Blair analyst M. Phipps now forecasts that the biopharmaceutical company will earn $1.03 per share for the quarter, down from their previous estimate of $1.52. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. Bristol Myers Squibb had a return on equity of 87.62% and a net margin of 11.38%. The business had revenue of $11.20 billion for the quarter, compared to analysts’ expectations of $10.77 billion. During the same period in the prior year, the firm posted ($4.40) EPS. The firm’s quarterly revenue was down 5.6% on a year-over-year basis.

Several other equities research analysts also recently commented on BMY. Wall Street Zen downgraded Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Friday, June 6th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol Myers Squibb in a report on Tuesday, April 8th. UBS Group reduced their price target on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a research note on Friday, April 11th. Morgan Stanley lowered their price objective on shares of Bristol Myers Squibb from $36.00 to $34.00 and set an “underweight” rating on the stock in a research report on Thursday, July 10th. Finally, Cantor Fitzgerald restated a “neutral” rating and issued a $55.00 target price on shares of Bristol Myers Squibb in a report on Tuesday, April 22nd. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Bristol Myers Squibb has an average rating of “Hold” and a consensus target price of $57.69.

Bristol Myers Squibb Stock Down 1.8%

BMY stock opened at $46.47 on Wednesday. The stock has a market capitalization of $94.57 billion, a P/E ratio of 17.41, a P/E/G ratio of 2.42 and a beta of 0.36. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. Bristol Myers Squibb has a 1-year low of $40.09 and a 1-year high of $63.33. The business has a fifty day moving average price of $47.43 and a 200-day moving average price of $53.10.

Bristol Myers Squibb Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Investors of record on Thursday, July 3rd will be given a dividend of $0.62 per share. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 annualized dividend and a yield of 5.34%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 92.88%.

Insider Transactions at Bristol Myers Squibb

In related news, EVP Samit Hirawat purchased 4,250 shares of Bristol Myers Squibb stock in a transaction on Friday, April 25th. The stock was acquired at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the completion of the transaction, the executive vice president directly owned 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.07% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Thoroughbred Financial Services LLC grew its stake in Bristol Myers Squibb by 1.1% during the 4th quarter. Thoroughbred Financial Services LLC now owns 17,763 shares of the biopharmaceutical company’s stock valued at $1,004,000 after acquiring an additional 190 shares in the last quarter. Marcum Wealth LLC lifted its stake in Bristol Myers Squibb by 1.0% in the 1st quarter. Marcum Wealth LLC now owns 19,296 shares of the biopharmaceutical company’s stock worth $1,177,000 after purchasing an additional 193 shares in the last quarter. Beacon Investment Advisory Services Inc. grew its position in shares of Bristol Myers Squibb by 2.7% in the first quarter. Beacon Investment Advisory Services Inc. now owns 8,063 shares of the biopharmaceutical company’s stock valued at $492,000 after purchasing an additional 212 shares in the last quarter. Leelyn Smith LLC increased its holdings in shares of Bristol Myers Squibb by 0.5% in the fourth quarter. Leelyn Smith LLC now owns 47,699 shares of the biopharmaceutical company’s stock valued at $2,698,000 after purchasing an additional 215 shares during the last quarter. Finally, Heron Bay Capital Management increased its holdings in shares of Bristol Myers Squibb by 2.1% in the fourth quarter. Heron Bay Capital Management now owns 10,795 shares of the biopharmaceutical company’s stock valued at $611,000 after purchasing an additional 220 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.